HTPB effectively inhibits A549 xenograft growth without significant side effects.

Abstract

<p>(<b>A</b>) Balb/c nude mice bearing the established A549 tumors (∼50 mm³) were treated with HTPB via intraperitoneal (left panel) or oral administration (right panel) for three weeks (3 days/week). A known HDAC inhibitor, SAHA, was used for comparison in intraperitoneal experiments. The tumor volumes of mice were measured twice weekly. Points, mean; bars, ±SEM. Three mice per group for intraperitoneal injection and five mice per group for oral treatment were used in the xenograft experiment. (<b>B</b>) The tumor weights of mice were measured. P values were for comparisons with DMSO or vehicle control (* <i>P</i><0.05, ** <i>P</i><0.01). (<b>C</b>) HTPB treatments did not cause significant body weight loss of tested animals. (<b>D</b>) Hematological biochemistry tests including GOT, GPT, albumin and creatinine were examined and the results showed no significant differences between HTPB treatment and DMSO or solvent control.</p

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the following location(s):}

https://figshare.com/articles/... (external link)